1. **BASELINE DATA**

Autologous stem cell collection strategy

[ ]  Bone marrow harvest

[ ]  Cytokine mobilization

[ ]  G-CSF

 [ ]  Plerixafor

 [ ]  G-CSF and Plerixafor

 [ ]  Other

[ ]  Chemotherapy mobilization

 [ ]  Cyclophoshamide

 [ ]  Other

[ ]  Gene modification technique

[ ]  Viral transduction

 [ ]  Ƴ-Retroviral

[ ]  Lentiviral

[ ]  Other

[ ]  Vector construct (Gene Cassette, Insulator)

[ ]  Gene editing

[ ]  CRISPER-Cas9

[ ]  TALEN

[ ]  ZFN

[ ]  RGEN

[ ]  Other

[ ]  Gene target

[ ]  γ-globin

[ ]  β-globin

[ ]  BCL11A

Transduction/Editing efficiency (%cells)

Cryopreservation

[ ]  Yes [ ]  No

[ ]  %DMSO

1. **POST THERAPY MONITORING**

(same frequency as reporting forms to be included on each form (e.g., 3 monthly intervals for the first 2 years, then every 6 months until year 5, then annually)

Date sample drawn:

Tissue monitoring site:

[ ]  Peripheral blood

[ ]  Bone marrow

 [ ]  Cells sorted?

 [ ]  Yes [ ]  No

 [ ]  Immunophenotype

Method

[ ]  RFLP

[ ]  Sanger sequencing

[ ]  Western Blot

[ ]  NGS

[ ]  TIDE3

[ ]  Reporter gene assay

 [ ]  Specify

[ ]  Other

Determination of immunogenicity

[ ]  [further discussion]